Strs Ohio Acquires 800 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Strs Ohio increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 12.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,400 shares of the medical equipment provider’s stock after buying an additional 800 shares during the period. Strs Ohio’s holdings in Lantheus were worth $458,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Silverberg Bernstein Capital Management LLC bought a new position in Lantheus in the 4th quarter worth approximately $1,385,000. Natixis Advisors L.P. lifted its stake in Lantheus by 172.8% in the 3rd quarter. Natixis Advisors L.P. now owns 52,530 shares of the medical equipment provider’s stock worth $3,649,000 after purchasing an additional 33,273 shares in the last quarter. American Century Companies Inc. lifted its stake in Lantheus by 41.9% in the 3rd quarter. American Century Companies Inc. now owns 1,300,904 shares of the medical equipment provider’s stock worth $90,387,000 after purchasing an additional 384,093 shares in the last quarter. Boston Partners lifted its stake in Lantheus by 15.2% in the 3rd quarter. Boston Partners now owns 512,930 shares of the medical equipment provider’s stock worth $35,326,000 after purchasing an additional 67,729 shares in the last quarter. Finally, Lazard Asset Management LLC lifted its stake in Lantheus by 60.5% in the 3rd quarter. Lazard Asset Management LLC now owns 336,946 shares of the medical equipment provider’s stock worth $23,410,000 after purchasing an additional 126,947 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on LNTH. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. B. Riley increased their target price on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. JMP Securities restated a “market outperform” rating and set a $100.00 price objective on shares of Lantheus in a research report on Friday, February 23rd. Finally, Truist Financial restated a “buy” rating and set a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $104.71.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $65.56 on Monday. The stock has a market cap of $4.49 billion, a PE ratio of 14.13 and a beta of 0.53. The company’s fifty day moving average is $61.62 and its 200 day moving average is $62.64. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $100.85. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. The company had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. Research analysts anticipate that Lantheus Holdings, Inc. will post 5.96 earnings per share for the current year.

Insider Buying and Selling

In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the sale, the director now owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. Insiders have sold a total of 94,545 shares of company stock worth $6,169,936 in the last 90 days. 1.50% of the stock is owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.